Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Mayo Clinic pilot study demonstrates safety, feasibility of delivering chemotherapy at home

Findings from a pilot study conducted by Mayo Clinic researchers suggest that chemotherapy can be safely delivered in patients’ homes.

March 27, 2026

Vol.52 No.12

In Brief

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

YOU MAY BE INTERESTED IN

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Mayo Clinic pilot study demonstrates safety, feasibility of delivering chemotherapy at home

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

START, Trialing collaborate to expand access to oncology clinical trials across Europe

Renew today!

Subscriber content

Never miss an issue!

Login